FDA approves new treatment for severe neutropenia in certain cancer patients

by FDA on August 29, 2012

in FDA Alerts

The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

This is a summary of a Press Release issued by the Food and Drug Administration (FDA). The link below will take you to the original press release containing complete information, including instructions about what to do if you are affected.

View Full Details Of Original FDA Press Release Here.

Leave a Comment

Previous post:

Next post: